DBV Technologies S.A. (DBVT) vs 4D Molecular Therapeutics (FDMT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
4D Molecular Therapeutics (FDMT) has outperformed DBV Technologies S.A. (DBVT) over the past year, losing 5.6% versus a loss of 34.4%. Over five years, DBVT leads with a +50.3% price change compared with -53.6% for FDMT. 4D Molecular Therapeutics is the larger company by market cap ($576.8 million vs $566.8 million), about 1.0 times the size.
4D Molecular Therapeutics converts more of its revenue into profit, with a net margin of -164.4% versus -2607.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DBVT | FDMT |
|---|---|---|
| Share price | $9.02 | $10.23 |
| Market cap | $566.82M | $576.76M |
| 1-day change | -4.25% | -4.57% |
| YTD return | -52.95% | +36.40% |
| 1-year return | -34.40% | -5.63% |
| 5-year return | +50.33% | -53.61% |
| EPS (TTM) | $-3.00 | $-2.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $5.64M | $85.21M |
| Revenue growth (YoY) | +35.77% | +230194.59% |
| Net income (latest FY) | $-146.95M | $-140.11M |
| Operating margin | -2609.23% | -187.24% |
| Net margin | -2607.29% | -164.43% |
| 52-week high | $26.19 | $16.93 |
| 52-week low | $8.63 | $6.96 |
| Distance from 52-week high | -65.55% | -39.57% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +305.10% | +174.58% |
| Average volume | 352.88K | 967.00K |
| Shares outstanding | 62.84M | 56.38M |
| Employees | 179 | 196 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FDMT has outperformed DBVT by 28.8 percentage points over the past year.
- 4D Molecular Therapeutics is more profitable, keeping -164.4 cents of every revenue dollar as net income versus -2607.3 cents for DBV Technologies S.A..
- 4D Molecular Therapeutics grew revenue faster in its latest fiscal year (+230194.59% vs +35.77%).
About DBV Technologies S.A.
DBVT stock →DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 179 employees
About 4D Molecular Therapeutics
FDMT stock →4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 196 employees
DBVT vs FDMT FAQ
Which is bigger, DBV Technologies S.A. or 4D Molecular Therapeutics?
4D Molecular Therapeutics (FDMT) is larger, with a market capitalization of $576.76M compared with $566.82M for DBV Technologies S.A. (DBVT).
Which stock has performed better over the past year, DBVT or FDMT?
FDMT returned -5.63% over the past 12 months, compared with -34.40% for DBVT (price return, excluding dividends). Past performance does not predict future results.
Are DBV Technologies S.A. and 4D Molecular Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.